Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Howe Sound Research | PRODUCT CODE: 1309750

Cover Image

PUBLISHER: Howe Sound Research | PRODUCT CODE: 1309750

Molecular Diagnostics for Cancer. Markets Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides and Customization. 2023 to 2027

PUBLISHED:
PAGES: 419 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 6995
PDF (Five User License)
USD 10495
PDF (Enterprise License)
USD 13995

Add to Cart

OVERVIEW:

After a pandemic interruption the market for Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 120 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • minimal residual disease testing
  • emergence of new economies with large markets
  • physician diagnostics being displaced by new intelligent diagnostic tests

Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Cancer MDx - Strategic Situation Analysis
  • 1.2 Guide for Executives, Marketing, and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 What are Molecular Diagnostics?
  • 2.2 The Diagnostics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Methodology
    • 2.4.1 Methodology
    • 2.4.2 Sources
    • 2.4.3 Authors
  • 2.5 Perspective: Healthcare and the IVD Industry
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview

  • 3.1 Market Segments
    • 3.1.1 Traditional Market Segmentation
    • 3.1.2 Laboratory Focus and Segmentation
  • 3.2 Industry Structure
    • 3.2.1 Hospital Testing Share
    • 3.2.2 Economies of Scale
    • 3.2.3 Physician Office Lab's
    • 3.2.4 Physician's and POCT

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 New Diagnostics Create New Markets
    • 4.1.2 New Roles for Diagnostics
    • 4.1.3 The Aging Effect
    • 4.1.4 Expanding the Pharmaceutical Toolbox
    • 4.1.5 Regulatory Retreat
  • 4.2 Factors Limiting Growth
    • 4.2.1 Falling Prices
    • 4.2.2 Lower Costs
    • 4.2.3 Wellness has a Downside
  • 4.3 Instrumentation, Automation and Diagnostic Trends
    • 4.3.1 Traditional Automation and Centralization
    • 4.3.2 The New Automation, Decentralization and Point Of Care
    • 4.3.3 Instruments Key to Market Share
    • 4.3.4 Bioinformatics Plays a Role
    • 4.3.5 PCR Takes Command
    • 4.3.6 Next Generation Sequencing Fuels a Revolution
    • 4.3.7 NGS Impact on Pricing
    • 4.3.8 Whole Genome Sequencing, A Brave New World
    • 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
    • 4.3.10 Shifting Role of Diagnostics
    • 4.3.11 Multiplexing and Foundation One
    • 4.3.12 Pharmacogenomics Technology
    • 4.3.13 Gene Editing and Gene Therapy

5 Molecular Diagnostics Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 Grail Cancer Test Faces New Clinical Questions
  • 5.3 Freenome Acquires Cancer Dx Firm Oncimmune
  • 5.4 Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
  • 5.5 Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
  • 5.6 Digital Pathology Meets Cancer Sequencing
  • 5.7 Exact Sciences Preps Expanded Oncology Portfolio
  • 5.8 Qiagen Details Oncology Plans for Digital PCR Platform
  • 5.9 Sema4 Exiting Reproductive Health Screening
  • 5.10 Thermo Fisher Introduces Cancer Profiling Assay
  • 5.11 Genomic Test IDs Cysts Likely to Progress to Cancer
  • 5.12 Naveris to Commercialize Virus-Related Cancer Tests
  • 5.13 Larger Liquid Biopsy Panels Loom
  • 5.14 Halo Diagnostics to Offer Genomic Profiling Tests
  • 5.15 BillionToOne Raises $125M
  • 5.16 Local Cancer Genomic Profiling Options Grow
  • 5.17 German MDx Firm Mainz Biomed Raises $10M in IPO
  • 5.18 Guardant Health Q3 Revenues Up 27 Percent
  • 5.19 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
  • 5.20 Nucleix to Invest in Early-Stage Lung Cancer Dx
  • 5.21 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
  • 5.22 Grail Gets Approval for Galleri Multicancer Test
  • 5.23 Finnish Firms to Form Point-of-Care Testing Firm
  • 5.24 Datar Cancer Genetics Expands to Dx and Screening
  • 5.25 HTG Molecular Diagnostics: HTG Transcriptome Panel
  • 5.26 PacBio's Omniome Acquisition Shortens Path to Clinical
  • 5.27 Invitae to Acquire Genosity for $200M
  • 5.28 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
  • 5.29 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
  • 5.30 Natera Revenues Grow 35 Percent
  • 5.31 AnchorDx Closes $40M Financing Round
  • 5.32 Exact Sciences Strategy for End-to-End Cancer Testing
  • 5.33 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch

6 Profiles of Key MDx Companies

  • 6.1 10x Genomics, Inc.
  • 6.2 Abbott Laboratories
  • 6.3 AccuraGen Inc.
  • 6.4 Adaptive Biotechnologies
  • 6.5 Aethlon Medical
  • 6.6 Agilent/Dako
  • 6.7 Anchor Dx
  • 6.8 ANGLE plc
  • 6.9 ARUP Laboratories
  • 6.10 AVIVA Systems Biology
  • 6.11 Baylor Miraca Genetics Laboratories
  • 6.12 Beckman Coulter Diagnostics
  • 6.13 Becton, Dickinson and Company
  • 6.14 BGI Genomics Co. Ltd
  • 6.15 BillionToOne
  • 6.16 Bioarray Genetics
  • 6.17 Biocartis
  • 6.18 Biocept, Inc.
  • 6.19 Biodesix Inc.
  • 6.20 BioFluidica
  • 6.21 BioGenex
  • 6.22 BioIVT
  • 6.23 Biolidics Ltd
  • 6.24 bioMérieux Diagnostics
  • 6.25 Bioneer Corporation
  • 6.26 Bio-Rad Laboratories, Inc
  • 6.27 Bio-Reference Laboratories
  • 6.28 Bio-Techne
  • 6.29 Bioview
  • 6.30 Bolidics
  • 6.31 Boreal Genomics
  • 6.32 Bristol-Myers Squibb
  • 6.33 Burning Rock
  • 6.34 Cardiff Oncology
  • 6.35 Caris Molecular Diagnostics
  • 6.36 Castle Biosciences, Inc.
  • 6.37 Celemics
  • 6.38 CellCarta
  • 6.39 CellMax Life
  • 6.40 Cepheid (Danaher)
  • 6.41 Charles River Laboratories
  • 6.42 Circulogene
  • 6.43 Cizzle Biotech
  • 6.44 Clinical Genomics
  • 6.45 Cytolumina Technologies Corp.
  • 6.46 Datar Cancer Genetics Limited
  • 6.47 Diagnologix LLC
  • 6.48 Diasorin S.p.A.
  • 6.49 Dxcover
  • 6.50 Enzo Biochem
  • 6.51 Epic Sciences
  • 6.52 Epigenomics AG
  • 6.53 Eurofins Scientific
  • 6.54 Exact Sciences
  • 6.55 Fabric Genomics
  • 6.56 Fluxion Biosciences
  • 6.57 Freenome
  • 6.58 FUJIFILM Wako Diagnostics
  • 6.59 Fulgent Genetics
  • 6.60 Fyr Diagnostics
  • 6.61 GeneFirst Ltd.
  • 6.62 Genetron Holdings
  • 6.63 GenomOncology
  • 6.64 GILUPI Nanomedizin
  • 6.65 Guardant Health
  • 6.66 HansaBiomed
  • 6.67 HeiScreen
  • 6.68 Helomics
  • 6.69 HTG Molecular Diagnostics
  • 6.70 iCellate
  • 6.71 ICON PLC
  • 6.72 Illumina
  • 6.73 Incell Dx
  • 6.74 Inivata
  • 6.75 INOVIQ
  • 6.76 Integrated Diagnostics
  • 6.77 Invitae Corporation
  • 6.78 Invivogen
  • 6.79 Invivoscribe
  • 6.80 Janssen Diagnostics
  • 6.81 Lunglife AI Inc
  • 6.82 MDNA Life SCIENCES, Inc.
  • 6.83 MDx Health
  • 6.84 Menarini Silicon Biosystems
  • 6.85 Mesa Laboratories, Inc.
  • 6.86 Millipore Sigma
  • 6.87 Miltenyi Biotec
  • 6.88 miR Scientific
  • 6.89 Myriad Genetics/Myriad RBM
  • 6.90 NantHealth, Inc.
  • 6.91 Natera
  • 6.92 NeoGenomics
  • 6.93 NGeneBio
  • 6.94 Novogene Bioinformatics Technology Co., Ltd.
  • 6.95 Oncocyte
  • 6.96 OncoDNA
  • 6.97 Ortho Clinical Diagnostics
  • 6.98 Oxford Nanopore Technologies
  • 6.99 PamGene
  • 6.100 Panagene
  • 6.101 Perkin Elmer
  • 6.102 Personal Genome Diagnostics
  • 6.103 Personalis
  • 6.104 Precipio
  • 6.105 Precision Medicine Group
  • 6.106 PrecisionMed
  • 6.107 Predicine
  • 6.108 Promega
  • 6.109 Qiagen
  • 6.110 Rarecells SAS
  • 6.111 RareCyte
  • 6.112 Roche Molecular Diagnostics
  • 6.113 Screencell
  • 6.114 Sema4 Holdings
  • 6.115 Sense Biodetection
  • 6.116 Siemens Healthineers
  • 6.117 simfo GmbH
  • 6.118 Singlera Genomics Inc.
  • 6.119 Singulomics
  • 6.120 SkylineDx
  • 6.121 Standard BioTools
  • 6.122 Sysmex Inostics
  • 6.123 Tempus Labs, Inc.
  • 6.124 Thermo Fisher Scientific Inc.
  • 6.125 Todos Medical
  • 6.126 Variantyx
  • 6.127 Veracyte
  • 6.128 Volition
  • 6.129 Vortex Biosciences
  • 6.130 Vyant Bio
  • 6.131 Zhejiang Orient Gene Biotech

7 The Global Market for MDx Cancer

  • 7.1 MDx Cancer - Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Cancer Type - Overview
    • 7.2.1 Table - Global Market by Cancer Type
    • 7.2.2 Chart - Global Market by Cancer Type - Base/Final Comparison
    • 7.2.3 Chart - Global Market by Cancer Type - Base Year
    • 7.2.4 Chart - Global Market by Cancer Type -Final Year
    • 7.2.5 Chart - Global Market by Cancer Type - Share by Year
    • 7.2.6 Chart - Global Market by Cancer Type - Segment Growth
  • 7.3 Global Market by Product Type - Overview
    • 7.3.1 Table - Global Market by Product Type
    • 7.3.2 Chart - Global Market by Product Type - Base/Final Comparison
    • 7.3.3 Chart - Global Market by Product Type - Base Year
    • 7.3.4 Chart - Global Market by Product Type -Final Year
    • 7.3.5 Chart - Global Market by Product Type - Share by Year
    • 7.3.6 Chart - Global Market by Product Type - Segment Growth
  • 7.4 Global Market by Place - Overview
    • 7.4.1 Table - Global Market by Place
    • 7.4.2 Chart - Global Market by Place - Base/Final Comparison
    • 7.4.3 Chart - Global Market by Place - Base Year
    • 7.4.4 Chart - Global Market by Place -Final Year
    • 7.4.5 Chart - Global Market by Place - Share by Year
    • 7.4.6 Chart - Global Market by Place - Segment Growth

8 Global Market by Cancer Type

  • 8.1 MDx Breast Cancer
    • 8.1.1 Table Breast Cancer Testing - by Country
    • 8.1.2 Chart - Breast Cancer Testing Growth
  • 8.2 MDx Colorectal Cancer
    • 8.2.1 Table Colorectal Cancer Testing - by Country
    • 8.2.2 Chart - Colorectal Cancer Testing Growth
  • 8.3 MDx Cervical Cancer
    • 8.3.1 Table Cervical Cancer Testing - by Country
    • 8.3.2 Chart - Cervical Cancer Testing Growth
  • 8.4 MDx Lung Cancer
    • 8.4.1 Table Lung Cancer Testing - by Country
    • 8.4.2 Chart - Lung Cancer Testing Growth
  • 8.5 MDx Prostate
    • 8.5.1 Table Prostate Testing - by Country
    • 8.5.2 Chart - Prostate Testing Growth
  • 8.6 MDx Melanoma Cancer
    • 8.6.1 Table Melanoma Cancer Testing - by Country
    • 8.6.2 Chart - Melanoma Cancer Testing Growth
  • 8.7 MDx Blood
    • 8.7.1 Table Blood Testing - by Country
    • 8.7.2 Chart - Blood Testing Growth
  • 8.8 MDx Companion Dx Development
    • 8.8.1 Table Companion Dx Development - by Country
    • 8.8.2 Chart - Companion Dx Development Growth
  • 8.9 MDx Other Cancer
    • 8.9.1 Table Other Cancer Testing - by Country
    • 8.9.2 Chart - Other Cancer Testing Growth

9 Global Market by Product Type

  • 9.1 MDx Instruments
    • 9.1.1 Table Instruments - by Country
    • 9.1.2 Chart - Instruments Growth
  • 9.2 MDx Reagents
    • 9.2.1 Table Reagents - by Country
    • 9.2.2 Chart - Reagents Growth
  • 9.3 MDx Software and Services
    • 9.3.1 Table Software and Services - by Country
    • 9.3.2 Chart - Software and Services Growth

10 Global Market by Place

  • 10.1 MDx Clinical Laboratory
    • 10.1.1 Table Clinical Laboratory - by Country
    • 10.1.2 Chart - Clinical Laboratory Growth
  • 10.2 MDx Pharmaceutical
    • 10.2.1 Table Pharmaceutical - by Country
    • 10.2.2 Chart - Pharmaceutical Growth
  • 10.3 MDx Research
    • 10.3.1 Table Research - by Country
    • 10.3.2 Chart - Research Growth

11 Cancer Treatment and Trials

  • 11.1 FDA Approvals by Year and Application
  • 11.2 Clinical Trials Starts
  • 11.3 Prevalence of Cancer Treatments

12 Appendices

  • 12.1 United States Medicare System: Clinical Laboratory Fees Schedule
  • 12.2 The Most Used IVD Assays
  • 12.3 The Highest Grossing Assays
  • 12.4 FDA Approved Human Genetic Tests
  • 12.5 FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1 Clinical Laboratory Departments and Segments
  • Table 2 Laboratory Management Focus - Different Approaches
  • Table 3 Key Segmentation Variables Going Forward
  • Table 4 Five Factors Driving Growth
  • Table 5 Factors Limiting Growth
  • Table 6 Seven Key Diagnostic Laboratory Technology Trends
  • Table 7 Global MDx Cancer Market by Region
  • Table 8 Global Market by Cancer Type
  • Table 9 Global Market by Product Type
  • Table 10 Global Market by Place
  • Table 11 MDx Breast Cancer by Country
  • Table 12 MDx Colorectal Cancer by Country
  • Table 13 Cervical Cancer Testing by Country
  • Table 14 Lung Cancer Testing by Country
  • Table 15 Prostate Testing by Country
  • Table 16 Melanoma Cancer Testing by Country
  • Table 17 MDx Blood by Country
  • Table 18 MDx Companion Dx Development by Country
  • Table 19 MDx Other Cancer Testing by Country
  • Table 20 MDx Instruments by Country
  • Table 21 MDx Reagents by Country
  • Table 22 Software and Services by Country
  • Table 23 MDx Clinical Laboratory by Country
  • Table 24 MDx Pharmaceutical by Country
  • Table 25 Research by Country
  • Table 26 Clinical Lab Fee Schedule
  • Table 1 The Most Common Assays
  • Table 2 Largest Revenue Assays

Table of Figures

  • Figure 1 Global Healthcare Spending
  • Figure 2 The Lab Test Pie
  • Figure 3 Population by Age Group
  • Figure 4 Health Care Consumption by Age
  • Figure 5 Cancer Incidence - Age at Diagnosis
  • Figure 6 Centralized vs. Decentralized Laboratory Service
  • Figure 7 A Highly Multiplexed Syndromic Testing Unit
  • Figure 8 The Real Cost to Sequence the Human Genome
  • Figure 9 The Codevelopment Process
  • Figure 10 Comparing MDx Diagnostic and Traditional Testing
  • Figure 11 Global Market Shares Base Year
  • Figure 12 MDx Market by Cancer - Base vs. Final
  • Figure 13 Cancer Market Base Year
  • Figure 14 Cancer Market Final Year
  • Figure 15 MDx Cancer Share by Year
  • Figure 16 MDx Cancer Segment Growth Rates
  • Figure 17 MDx Market by Product - Base vs. Final
  • Figure 18 Product Market Base Year
  • Figure 19 Product Market Final Year
  • Figure 20 MDx Product Share by Year
  • Figure 21 MDx Product Segment Growth Rates
  • Figure 22 MDx Market by Place - Base vs. Final
  • Figure 23 Place Market Base Year
  • Figure 24 Place Market Final Year
  • Figure 25 MDx Place Share by Year
  • Figure 26 MDx Place Segment Growth Rates
  • Figure 27 Breast Cancer Testing Growth
  • Figure 28 Colorectal Cancer Testing Growth
  • Figure 29 Cervical Cancer Testing Growth
  • Figure 30 Lung Cancer Testing Growth
  • Figure 31 Prostate Testing Growth
  • Figure 32 Melanoma Cancer Testing Growth
  • Figure 33 Blood Testing Growth
  • Figure 34 Companion Dx Development Growth
  • Figure 35 Other Cancer Testing Growth
  • Figure 36 Instruments Growth
  • Figure 37 Reagents Growth
  • Figure 38 Software and Services Growth
  • Figure 39 Clinical Laboratory Growth
  • Figure 40 Pharmaceutical Growth
  • Figure 41 Research Growth
  • Figure 42 FDA Approvals by Year and Application
  • Figure 43 Clinical Trials for Oncology by Year
  • Figure 44 Pie Chart of Prevalence of Cancer Treatments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!